AEON Biopharma, Inc.
AEON NYSE· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.24
KIRA · Stoqly’s AI analyst, in plain words
- AEON Biopharma, Inc. lost $39.2M in fiscal 2025.
- Free cash flow was −$17.3M in fiscal 2025, — of revenue.
Market cap
$12.1M
P/E
—
Revenue
—
Net income
−$39.2M
Free cash flow
−$17.3M
Operating margin
—
AEON Biopharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$39.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What AEON Biopharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- AEON Biopharma, Inc.
- CIK
- 0001837607
AEON Biopharma, Inc. · AEON
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Net income | $8.2M | −$52.6M | — | −$39.2M |
| Diluted EPS | — | −$0.38 | — | −$3.95 |
| Cash | ||||
| Cash from operations | −$1.5M | −$35.6M | — | −$17.3M |
| Capital expenditure | — | $0.3M | — | $0.0M |
| Free cash flow | — | −$35.9M | — | −$17.3M |
| Debt and strength | ||||
| Cash and short-term investments | $0.5M | $9.7M | $0.0M | $3.0M |
| Shareholders' equity | −$16.9M | −$288M | −$28.6M | −$55.0M |
| Current ratio | 1.0x | 0.1x | 0.1x | 0.5x |
| Returns and quality | ||||
| Altman Z'' | −1.2 | −220.2 | — | −296.6 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
AEON Biopharma, Inc. · AEON
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.24 a share, the company is worth $12.1M.
Source: SEC EDGAR XBRL filings (CIK 0001837607). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.